{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:22:38Z","timestamp":1770751358426,"version":"3.50.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12185-025-03966-6","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T11:25:51Z","timestamp":1741519551000},"page":"217-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma"],"prefix":"10.1007","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-1201","authenticated-orcid":false,"given":"Shuku","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Sawazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomiteru","family":"Togano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yotaro","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,9]]},"reference":[{"key":"3966_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/JEP.S265288","volume":"13","author":"M Offidani","year":"2021","unstructured":"Offidani M, Corvatta L, Mor\u00e8 S, Olivieri A. Novel experimental drugs for treatment of multiple myeloma. J Exp Pharmacol. 2021;13:245\u201364.","journal-title":"J Exp Pharmacol"},{"key":"3966_CR2","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","volume":"8","author":"B Diamond","year":"2021","unstructured":"Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8:e422\u201332.","journal-title":"Lancet Haematol"},{"issue":"1","key":"3966_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41408-024-01102-x","volume":"14","author":"J Martinez-Lopez","year":"2024","unstructured":"Martinez-Lopez J, Lopez-Mu\u00f1oz N, Chari A, Dorado S, Barrio S, Arora S, et al. Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence. Blood Cancer J. 2024;14(1):13.","journal-title":"Blood Cancer J"},{"issue":"4","key":"3966_CR4","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"23","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;23(4):5988\u201399.","journal-title":"Blood Adv"},{"issue":"11","key":"3966_CR5","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582\u201396.","journal-title":"Lancet Oncol"},{"issue":"10218","key":"3966_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132\u201341.","journal-title":"Lancet"},{"issue":"2","key":"3966_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132\u201347.","journal-title":"N Engl J Med"},{"key":"3966_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48: 452458.","journal-title":"Bone Marrow Transplant"},{"key":"3966_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.2022016782","volume":"141","author":"B Paiva","year":"2023","unstructured":"Paiva B, Manrique I, Dimopoulos MA, Gay F, Min CK, Zweegman S, et al. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood. 2023;141:579\u201391.","journal-title":"Blood"},{"key":"3966_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102016","volume":"60","author":"S Oliva","year":"2023","unstructured":"Oliva S, Genuardi E, Paris L, D\u2019Agostino M, Rogers J, Rota-Scalabrini D, et al. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. EClinicalMedicine. 2023;60: 102016.","journal-title":"EClinicalMedicine"},{"issue":"7","key":"3966_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2023022083","volume":"143","author":"C Guerrero","year":"2024","unstructured":"Guerrero C, Puig N, Cedena MT, Calasanz MJ, Gutierrez NC, Fernandez M, et al. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma. Blood. 2024;143(7):597\u2013603.","journal-title":"Blood"},{"issue":"25","key":"3966_CR12","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.21.02228","volume":"40","author":"RM de Tute","year":"2022","unstructured":"de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022;40(25):2889\u2013900.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3966_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57\u201373.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3966_CR14","first-page":"1733","volume":"106","author":"HM Cherniawsky","year":"2021","unstructured":"Cherniawsky HM, Kukreti V, Reece D, Masih-Khan E, McCurdy A, Jimenez-Zepeda VH, et al. The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database Haematologica. Lancet Oncol. 2021;106(6):1733\u20136.","journal-title":"Lancet Oncol"},{"key":"3966_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102099","volume":"62","author":"JR Jones","year":"2023","unstructured":"Jones JR, Cairns DA, Menzies T, Pawlyn C, Davies FE, Sigsworth R, et al. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients: profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. EClinicalMedicine. 2023;62: 102099.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"3966_CR16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/blood.2021015220","volume":"140","author":"C Yamamoto","year":"2022","unstructured":"Yamamoto C, Minakata D, Koyama S, Sekiguchi K, Fukui Y, Murahashi R, et al. Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. Blood. 2022;140(6):594\u2013607.","journal-title":"Blood"},{"key":"3966_CR17","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03966-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03966-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03966-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:27:55Z","timestamp":1757143675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03966-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,9]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3966"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03966-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,9]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}